- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13 | 141 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year... ► Artikel lesen | |
| 25.02. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. announces a supplement to the offer document in respect of the recommended cash offer to the shareholders of Abliva AB (publ) | 3 | Cision News | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 20.02. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent | 2 | Cision News | ||
| 20.02. | Pharming Group N.V.: Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent | 3 | GlobeNewswire (USA) | ||
| 20.02. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.02. | Pharming completes bid for Abliva | 2 | Cision News | ||
| 07.02. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period | 3 | Cision News | ||
| 07.02. | Pharming Group N.V.: Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period | 132 | GlobeNewswire (Europe) | This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation... ► Artikel lesen | |
| 07.02. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. has received the necessary regulatory approval for the recommended cash offer to the shareholders of Abliva AB (publ) | 11 | Cision News | ||
| 21.01. | Pharming Group N.V.: Pharming Group to convene Extraordinary General Meeting of Shareholders | 2 | GlobeNewswire (USA) | ||
| 21.01. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO | 12 | Seeking Alpha | ||
| 21.01. | Pharming Group N.V.: Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer | 344 | GlobeNewswire (Europe) | Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice... ► Artikel lesen | |
| 15.01. | PHARMING TECHNOLOGIES B V: Offer document regarding Pharming Technologies B.V.'s recommended cash offer to the shareholders of Abliva AB (publ) | 6 | Cision News | ||
| 31.12.24 | Pharming Group (NASDAQ:PHAR) Trading 6.1% Higher - What's Next? | 4 | MarketBeat | ||
| 23.12.24 | Pharming Group (NASDAQ:PHAR) Trading 6.6% Higher - Should You Buy? | 6 | MarketBeat | ||
| 16.12.24 | Pharming pays $66M for Abliva and its 'potential blockbuster' mitochondrial disease med | 4 | FierceBiotech | ||
| 16.12.24 | Pharming Group offers to buy Sweden's Abliva for SEK 0.45/shr | 2 | Seeking Alpha | ||
| 16.12.24 | Pharming Group Offers To Acquire Abliva For SEK 0.45/shr In Cash | 3 | RTTNews |
Seite:
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEIDELBERG PHARMA | 2,630 | -1,50 % | AKTIONÄR-Tipp Telix Pharma: Top-News - auch für Heidelberg Pharma | Der australische Radiopharma-Spezialist Telix Pharmaceuticals knüpft an den positiven Newsflow der vergangenen Wochen und Monate nahtlos an. Im zweiten Versuch hat die US-Gesundheitsbehörde FDA den... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,080 | +0,75 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,262 | +0,53 % | Pacific Biosciences Of California, Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Pacific Biosciences of California, Inc. (PACB):Earnings: $3.57 million in Q4 vs. -$82.02 million in the same period last year.
EPS:... ► Artikel lesen | |
| CENTOGENE | 0,150 | +25,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,450 | +1,65 % | ICE - ATAI Life Sciences - Das war einfach! - Vorher, nachher | ||
| PHARMING | 0,870 | -0,29 % | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13 | Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year... ► Artikel lesen | |
| BIOMERIEUX | 115,60 | +2,30 % | QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology | PARIS (dpa-AFX) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements... ► Artikel lesen | |
| CYCLACEL | 0,310 | -8,82 % | Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership | ||
| SYROS PHARMACEUTICALS | 0,071 | -9,62 % | Syros Pharmaceuticals, Inc. Announces Voluntary Delisting from Nasdaq and SEC Deregistration | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed... ► Artikel lesen | |
| GENUS | 21,600 | +0,93 % | Genus HY Pre-Tax Profit Down; Declares Unchanged Interim Dividend Of 10.3p/shr | LONDON (dpa-AFX) - Genus plc (GNS.L) reported that its profit before tax for the six months ended 31 December 2024 dropped to 3.3 million pounds from last year's 14.3 million pounds. The latest... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,420 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 14,000 | -11,95 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and... ► Artikel lesen | |
| ABIONYX PHARMA | 1,390 | +9,62 % | ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances | Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application... ► Artikel lesen | |
| MEIRAGTX | 6,950 | +12,10 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,550 Euro und damit +1,18 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.
